Event-Driven Stocks

Merck

MRKNYSE

Other · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 4 gooddetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$65.01B$64.17B$60.12B$59.28B$48.70B$41.52B
Operating income——————
Net income$18.25B$17.12B$365.0M$14.52B$13.05B$7.07B
Total assets$136.87B$117.11B$106.67B$109.16B$105.69B$91.59B
Total liabilities——————
Equity$52.61B$46.31B$37.58B$45.99B$38.18B$25.32B
EPS (diluted)$7.28$6.74$0.14$5.71$5.14$2.78
Shares out.2.53B2.53B2.54B2.53B2.53B2.54B

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
28.1%
Return on equity
34.7%
Return on assets
13.3%
Return on capital (ROCE)
—
Liabilities / assets
—
Debt / equity
—
Book value / share
$20.83
Revenue growth (YoY)
1.3%
Net income growth (YoY)
6.6%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
1.3%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
80
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 4 good
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • VIOXXMar 26, 2004
  • FOSAMAXSep 17, 2003
  • CANCIDASJan 26, 2001
  • PEPCID RPDMay 28, 1998
  • TIAMATEOct 4, 1996
  • CHIBROXINJun 17, 1991
  • PRIMAXINDec 14, 1990
  • PRINZIDEFeb 16, 1989

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202629.1M3.6+10.9%
Apr 30, 202626.2M2.5-4.7%
Apr 15, 202627.5M3.3-0.8%
Mar 31, 202627.7M2.5-4.9%
Mar 13, 202629.1M3.1-6.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spin-offs from Merck (2)

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (8)